Oak Thistle LLC Makes New $1.50 Million Investment in Hologic, Inc. $HOLX

by · The Cerbat Gem

Oak Thistle LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 22,185 shares of the medical equipment provider’s stock, valued at approximately $1,497,000.

Several other institutional investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Hologic by 294.3% during the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after acquiring an additional 8,227,318 shares during the period. Invesco Ltd. grew its position in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Norges Bank acquired a new stake in Hologic during the 2nd quarter valued at $180,055,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares in the last quarter. Finally, Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. BNP Paribas cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Friday, November 21st. BNP Paribas Exane lowered shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Evercore ISI set a $78.00 price target on shares of Hologic and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Five investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.29.

View Our Latest Stock Report on HOLX

Hologic Stock Down 0.1%

Shares of Hologic stock opened at $74.93 on Thursday. The firm has a market cap of $16.70 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 2.13 and a beta of 0.70. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.34. The stock has a 50-day simple moving average of $73.45 and a 200-day simple moving average of $68.59.

Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.01 earnings per share. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).